Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective was to evaluate the effect of the consumption of dual probiotic strains containing Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032 on weight loss, body adiposity and inflammatory markers including lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in overweight subjects.
A randomized, double-blind, placebo-controlled study was conducted on 120 subjects with age between 20 and 65 years, nondiabetic (fasting blood glucose <126 mg/dL and 2-hour blood glucose <200 mg/dL), and overweight (25 kg/m2 ≤ body mass index (BMI) < 30 kg/m2). Over a 12 week test period, the probiotic group consumed 2 g of powder twice a day containing L. curvatus HY7601 and L. plantarum KY1032, while the placebo group consumed the same product without probiotics for 12 weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Probiotic group | Experimental | consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner. |
|
| Placebo group | Placebo Comparator | consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic group | Dietary Supplement | The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent. |
| Measure | Description | Time Frame |
|---|---|---|
| Fat percentage by dual-energy x-ray absorptiometry (DEXA) at baseline and 12-week follow-up | Fat percentage (%) | 12-week follow-up |
| Fat mass by DEXA at baseline and 12-week follow-up | Fat mass (g) | 12-week follow-up |
| Lean body mass by DEXA at baseline and 12-week follow-up | Lean body mass (g) | 12-week follow-up |
| Fat area by computed tomography (CT) at baseline and 12-week follow-up | Fat area (cm2) at levels of 1st lumbar (L1) vertebra and 4th lumbar (L4) vertebra | 12-week follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Total Cholesterol at baseline and 12-week follow-up | Total Cholesterol (mg/dL) | 12-week follow-up |
| HDL Cholesterol at baseline and 12-week follow-up | HDL Cholesterol (mg/dL) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jong Ho Lee, Ph.D. | Dept. of Food and Nutrition, College of Human Ecology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, South Korea | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| D015431 | Weight Loss |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo group | Dietary Supplement | The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent. |
|
| 12-week follow-up |
| LDL Cholesterol at baseline and 12-week follow-up | LDL Cholesterol (mg/dL) | 12-week follow-up |
| Triglyceride at baseline and 12-week follow-up | Triglyceride (mg/dL) | 12-week follow-up |
| High sensitivity C-reactive protein (hs-CRP) at baseline and 12-week follow-up | hs-CRP (mg/dL) | 12-week follow-up |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001836 | Body Weight Changes |